Does "off the shelf" mean cells without matching can be used for short durations like a few months for treatment?
Recent FATE News
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2026 08:05:00 PM
- The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed • GlobeNewswire Inc. • 03/18/2026 03:30:00 PM
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/04/2026 09:05:00 PM
- Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference • GlobeNewswire Inc. • 03/03/2026 09:05:00 PM
- Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them • PR Newswire (US) • 03/03/2026 03:02:00 PM
- Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them • PR Newswire (Canada) • 03/03/2026 03:02:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:07:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 02:04:07 PM
- Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates • GlobeNewswire Inc. • 02/26/2026 02:00:00 PM
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets • PR Newswire (US) • 01/26/2026 03:16:00 PM
- Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets • PR Newswire (Canada) • 01/26/2026 03:16:00 PM
- Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets • GlobeNewswire Inc. • 01/23/2026 05:56:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 09:03:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 09:02:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 09:00:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2026 09:04:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2026 09:03:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/09/2026 08:08:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/09/2026 08:08:01 PM
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/05/2026 09:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/29/2025 07:44:28 PM
- Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs • GlobeNewswire Inc. • 12/08/2025 01:00:00 PM
- Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference • GlobeNewswire Inc. • 11/25/2025 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 01:35:02 PM
